Indivior (NASDAQ:INDV) Director Acquires $27,427.25 in Stock

Indivior PLC (NASDAQ:INDV) Director Mark Stejbach acquired 775 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was purchased at an average cost of $35.39 per share, with a total value of $27,427.25. Following the acquisition, the director directly owned 16,847 shares of the company’s stock, valued at $596,215.33. This trade represents a 4.82% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Indivior Price Performance

Shares of INDV stock opened at $35.44 on Friday. The company has a market capitalization of $4.43 billion, a PE ratio of 38.52 and a beta of 0.75. The firm’s 50-day moving average is $34.16 and its two-hundred day moving average is $25.88. Indivior PLC has a 12 month low of $7.62 and a 12 month high of $38.00.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.34. The business had revenue of $314.00 million during the quarter, compared to analysts’ expectations of $257.66 million. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%. Sell-side analysts forecast that Indivior PLC will post 1.22 EPS for the current year.

Institutional Investors Weigh In On Indivior

Several institutional investors and hedge funds have recently modified their holdings of the company. CWM LLC acquired a new position in Indivior during the 3rd quarter worth about $25,000. Quarry LP acquired a new position in Indivior in the 3rd quarter valued at about $26,000. GAMMA Investing LLC increased its stake in Indivior by 544.6% during the fourth quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after purchasing an additional 1,013 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Indivior during the second quarter worth about $26,000. Finally, Plato Investment Management Ltd acquired a new stake in shares of Indivior during the third quarter worth about $52,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Morgan Stanley restated an “overweight” rating and issued a $36.00 target price on shares of Indivior in a research report on Wednesday, December 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Indivior in a research report on Friday, October 31st. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, November 3rd. Piper Sandler reaffirmed an “overweight” rating and issued a $41.00 target price (up previously from $27.00) on shares of Indivior in a research report on Friday, October 31st. Finally, Craig Hallum reiterated a “buy” rating and set a $41.00 price target on shares of Indivior in a research report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $32.71.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.